Related Experiment Video

Updated: Jan 2, 2026

Analysis of Cell Cycle Position in Mammalian Cells
12:19

Analysis of Cell Cycle Position in Mammalian Cells

Published on: January 21, 2012

61.2K

ARID1A prevents squamous cell carcinoma initiation and chemoresistance by antagonizing pRb/E2F1/c-Myc-mediated cancer

Qingyu Luo1, Xiaowei Wu1, Wan Chang1

  • 1State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

Cell Death and Differentiation
|December 14, 2019
PubMed

Insights

ARID1A suppresses squamous cell carcinoma (SCC) stemness and chemoresistance by inhibiting the E2F1/c-Myc pathway. Loss of ARID1A promotes SCC development and resistance to chemotherapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Squamous cell carcinoma (SCC) is an aggressive malignancy often resistant to chemotherapy, leading to poor patient outcomes.
  • The tumor-suppressive role of ARID1A is established in various cancers, but its function in SCCs and its relationship with cancer stemness are unclear.
  • Cancer stemness is a key driver of tumorigenesis and chemoresistance, yet its regulation by ARID1A in SCC remains uninvestigated.

Purpose of the Study:

  • To investigate the role of ARID1A in the development and progression of squamous cell carcinoma.
  • To elucidate the relationship between ARID1A, cancer stemness, and chemoresistance in SCC.
  • To identify the molecular mechanisms by which ARID1A regulates SCC stemness and chemoresistance.

Main Methods:

  • Utilized Arid1a conditional knockout mouse models to study SCC development.
  • Employed human SCC cell lines to assess the impact of ARID1A depletion on tumor initiation and stemness.
  • Conducted mechanistic studies involving protein-protein interactions, cell signaling pathway analysis (CDK/Rb/E2F1/c-Myc), and chemoresistance assays.
  • Evaluated the therapeutic potential of CDK inhibitors in ARID1A-deficient SCC models.

Main Results:

  • Arid1a knockout mice exhibited a high incidence of SCC in the tongue and esophagus.
  • ARID1A depletion promoted tumor initiation and enhanced cancer stemness in human SCC cells.
  • ARID1A was found to inhibit the interaction between cyclin-dependent kinases (CDKs) and retinoblastoma protein (Rb), thereby reducing Rb phosphorylation.
  • This inhibition suppressed E2F1 activity and subsequently reduced cancer stemness by inactivating c-Myc.
  • ARID1A depletion significantly increased SCC chemoresistance, which could be partially rescued by CDK inhibitors.

Conclusions:

  • ARID1A acts as a tumor suppressor in squamous cell carcinoma.
  • ARID1A inhibits cancer stemness and chemoresistance in SCC by regulating the CDK/Rb/E2F1/c-Myc signaling axis.
  • Targeting CDK activity may represent a therapeutic strategy for ARID1A-deficient SCCs.

More Related Videos

Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics11:28

Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics

Published on: May 11, 2016

8.9K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.5K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.6K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.1K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
5.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K